Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Charles Ross & Son introduced the DCB-5 Double Cone Tumble Blender, a five‑cubic‑foot unit designed for high‑density powder processing. The machine combines a stainless‑steel jacket, a 2 HP intensifier bar, and an integrated vacuum system to deliver repeatable homogeneity and simultaneous drying. It features a VFD‑driven motor, touch‑screen interface, and built‑in AI monitoring for predictive maintenance. The release emphasizes the equipment’s alignment with GMP requirements and its role in modernizing pharmaceutical batch operations.
Scientists have unveiled a zero‑shot learning framework that phenotypes maize cob geometry without any model retraining. The system combines text‑guided object detection, lightweight segmentation, and calibrated trait extraction, delivering 98‑100% detection accuracy and over 0.95 correlation for trait estimates. It...
Manish Garg of Hikma Pharmaceuticals highlighted how AI, personalized medicine, and smart manufacturing reshaped pharma in 2025 and set the agenda for 2026. AI accelerated drug discovery and clinical design, while niche, high‑value therapies gained prominence. Companies are regionalizing supply...
Researchers at Scripps have unveiled vCATCH, a whole‑body imaging platform that lights up covalent drugs at single‑cell resolution in mice. By attaching a tiny chemical handle to drugs and using highly selective click‑chemistry, the method tags each bound molecule with...
ArisGlobal’s senior VP Jason Bryant argues that both human‑in‑the‑loop (HITL) and human‑on‑the‑loop (HOTL) remain essential for deploying agentic AI in pharma. He uses an air‑traffic‑control analogy, portraying AI agents as aircraft and the orchestration layer as air‑traffic management. Bryant stresses...
If restoring youthful function in old tissues sounds radical, remember that surgery without pain once did to
The biotech community mourned the loss of several iconic figures in 2025, including Nobel laureate David Baltimore and industry pioneer Rutter. Their careers spanned groundbreaking scientific discoveries, the founding of biotech firms, and the cultivation of global research ecosystems. The...
In 2025 the pharmaceutical sector saw a surge of novel therapies, notably next‑generation biologics such as bispecifics, fusion proteins, multi‑specifics, and a wave of antibody‑drug conjugates (ADCs). A breakthrough sub‑category, antibody‑oligo conjugates (AOCs), gained traction for muscular dystrophy, highlighted by...
Sanofi has agreed to acquire two vaccine assets from Dynavax, including an approved hepatitis B vaccine and a late‑stage shingles candidate. The transaction, announced in late December 2025, adds to Sanofi’s existing vaccine portfolio and broadens its reach in both...
Colossal Biosciences was awarded the 2025 The Screamers Award for its overstated claim of de‑extincting the dire wolf. In reality the firm only introduced a handful of dire‑wolf‑related gene edits into existing gray wolves, leaving the animals genetically gray wolves....
Researchers analyzed over 340,000 Swedish hypertension patients and found that initiating treatment with angiotensin‑receptor blockers (ARBs) leads to markedly higher long‑term medication persistence. After five years, 80 % of ARB starters remained adherent, versus 65 % for calcium‑channel blockers, the next best...
A team led by Prof. Xu Cao at the Chinese Academy of Sciences has proposed an AI‑empowered breeding framework, dubbed DSAP, to accelerate the domestication of orphan crops such as fonio, tef, and cowpea. The strategy integrates de novo genome editing,...
BioCentury’s year‑end podcast highlights 2025 as a turning point for biotech, with revived market sentiment, robust M&A activity and a more assertive FDA under new leadership. Analysts spotlight the $4.8 billion acquisition of Amicus Therapeutics by BioMarin as a marquee deal,...
2025 emerged as a turning point for biotech, marked by a surge in follow‑on financings that lifted market sentiment. Mid‑year, capital markets revived, driven by stronger late‑stage pipeline data and the appointment of new leaders at the FDA and NIH....
Mereo BioPharma and Ultragenyx reported disappointing readouts from their bone disease programs, triggering sharp declines in both stocks. Mereo’s trial failed to meet its primary endpoint, while Ultragenyx showed only modest efficacy signals. The market reaction erased roughly 15% of...
Gabriella Rubert reflects on her tenure as host of the Inside Biotech podcast, discussing the challenges of translating complex science into engaging stories and the responsibility that comes with science communication. She emphasizes the power of storytelling to bridge biotech...
The Practical Fragments blog celebrated its thousandth post in 2025, highlighting a decade of fragment‑based drug discovery (FBDD) milestones. Key reviews covered fragment‑to‑lead successes, the rise of covalent fragments, AI‑driven cryptic pocket discovery, and extensive bibliometric analysis showing steady global...
ArisGlobal senior VP Jason Bryant explains that full autonomy for AI agents is off‑limits in pharmacovigilance, citing ethical and legal concerns. Instead, he advocates bounded autonomy managed by an orchestrator that can hand control to humans when needed. The discussion...
The 2025 stem‑cell roundup highlights five breakthrough developments: Capricor’s deramiocel for Duchenne muscular dystrophy is on track for FDA approval by 2026; three independent Parkinson’s trials reported encouraging early efficacy; Vertex’s diabetes program saw participants achieve insulin‑free periods; a Mass Brigham...
2025 proved pivotal for drug discovery, with the FDA approving 44 new therapies and several breakthrough candidates advancing to late‑stage trials. The most‑read case studies highlighted oral macrocycles, innovative PK engineering, and first‑in‑class modalities such as the pan‑RAS glue daraxonrasib...
University of Colorado researchers found that the FDA‑approved drug sargramostim, a synthetic GM‑CSF protein, reduced the blood biomarker UCH‑L1 of neuronal death by 40% in Alzheimer’s patients, bringing levels down to those seen in early life. The study also documented...
Using ultra‑high‑field 7 T MRI, researchers examined amygdala subnuclei volumes, network topology, and structural covariance in 73 PTSD patients, 78 trauma‑exposed controls, and 59 non‑trauma controls. Whole‑amygdala size was unchanged, but the lateral nucleus showed opposite volume shifts: larger left lateral...
Henrik Johanning of Epista Life Sciences outlines the European regulatory and manufacturing roadmap for 2026, emphasizing the operationalisation of modern quality risk management (QRM) and the need for tangible upgrades to meet EU GMP Annex 1 requirements. He highlights rising digital...
The PharmTech roundup reviews the ten most‑watched videos of 2025, revealing a industry pivot toward complex modalities such as AAV‑based gene therapies, high‑concentration biologics, and radiopharmaceuticals. Across the series, manufacturers stress the "CGT 2.0" model—flexible, automated, data‑driven production—to overcome scale‑up bottlenecks....
Researchers at SKKU, HKUST and Jeonbuk University unveiled SIDNEY, a graphene‑oxide‑wrapped hybrid electrode that enables real‑time, label‑free dopamine detection in living neurons and brain organoids. The nanostructured platform combines gold nanopillars with a thin graphene‑oxide coating, achieving a detection limit...
An Iowa civil court awarded a $1 million judgment against Omaha Stem Cells and its owner Travis Broughton for deceptive stem‑cell therapies. The ruling also ordered reimbursement of $810,477 to 76 patients, including an additional $20,000 penalty for targeting older adults....
The article revisits three recent biotech breakthroughs that felt like miracles: base‑edited CAR‑T cells (BE‑CAR7) delivering remission for relapsed T‑ALL, ex vivo gene‑corrected skin grafts curing severe junctional epidermolysis bullosa, and prenatal enzyme replacement therapy mitigating infantile Pompe disease. Each case...
In 2014 MIT researcher Dr. Stephanie Seneff warned that glyphosate would make half of all children autistic by 2025, a claim that has now been disproven. The blog post uses this missed prediction to illustrate a broader pattern where disinformation...
University of Utah researchers identified the gut bacterium Turicibacter as a potent modulator of metabolic health, showing it markedly reduces weight gain, blood sugar, and blood lipids in mice fed a high‑fat diet. The microbe’s effect stems from a suite...
University of St Andrews researchers have demonstrated a ruthenium‑catalysed semi‑hydrogenation that depolymerises household PET waste into ethyl‑4‑hydroxymethyl benzoate (EHMB). EHMB is a versatile intermediate for high‑value drugs such as the cancer therapy Imatinib, as well as tranexamic acid and the...
Utah authorities have filed felony charges against Dr. Paul William Winterton, Randall Matthew Relyea, and Jenny Astrid Fraizer for a pattern of unlawful activity at the Precision Pointe Regenerative Health clinic. The indictments include second‑degree felonies for communications fraud, third‑degree...
University of California‑Riverside researchers have engineered a DIY black‑soldier fly bioreactor that converts on‑site food waste into high‑protein larvae and nutrient‑dense frass. The system uses off‑the‑shelf materials, operates under a single caretaker, and yields roughly one pound of larvae per...
A BMJ Medicine study examined Medicare’s use of FDA accelerated‑approval cancer drugs from 2012‑2020. Of the 178,000 beneficiaries treated, only 45% received drugs that later proved to extend survival, adding an estimated 76,000 life‑years. The three most beneficial drugs accounted...
Former FDA official Henry I. Miller warns that the agency’s draft plan to place a black‑box warning on COVID‑19 vaccines lacks scientific justification. He notes that the proposal appears driven by political appointees, particularly HHS Secretary Robert F. Kennedy Jr., rather than robust...
In this retrospective episode, host and guest Mary Louise Smith reflect on Biotech Bytes' first year, sharing how the podcast began, the power of simple conversations for generating ideas, and the role of AI in streamlining work. Mary offers behind‑the‑scenes...
Researchers at Chuo University introduced a vibration‑induced local vortex (VILV) platform that creates highly uniform DNA condensate droplets using a low‑cost piezoelectric vibrator. The system replaces traditional microfluidic pumps with stable micro‑vortex arrays generated on a simple micropillar device, enabling...
Gepotidacin (Blujepa®), an oral bacterial type II topoisomerase inhibitor developed by GSK, received approval in April 2025 for uncomplicated urinary‑tract infections and gonorrhea. The drug emerged from an unbiased antibacterial screening program and represents the first new oral class of antibiotics targeting...
Northwestern and Stanford researchers have engineered a fully synthetic, cell‑free metabolism called the Reductive Formate Pathway (ReForm) that converts CO₂‑derived formate into acetyl‑CoA and subsequently into malate, a high‑value chemical. The pathway relies on five engineered enzymes arranged in six...
Researchers at Hebrew University identified a tiny phage‑encoded RNA, PreS, that reprograms bacterial host cells during infection. PreS binds to the folded region of the bacterial dnaN mRNA, unfolding it and boosting production of the DnaN replication protein. The resulting...
In this episode, Dr. Sonia Contera discusses how physics and nanotechnology can illuminate the mechanics and shape of biological systems, from molecular assemblies to whole organs. She explains her interdisciplinary approaches—such as nanoscale imaging and mechanical probing—to study pancreatic tumors,...
The U.S. Centers for Disease Control and Prevention awarded a $1.6 million grant to the University of Southern Denmark to conduct a five‑year randomized trial of hepatitis B vaccine timing in newborns in Guinea‑Bissau. The study, led by Christine Stabell Benn and Peter Aaby,...
A low‑dose adult stem‑cell transplant (RPESC‑RPE‑4W) for dry age‑related macular degeneration met primary safety endpoints and showed visual acuity gains. In a separate development, a child died during a pioneering gene‑therapy trial that used engineered viruses to cross the blood‑brain...
Insmed’s experimental therapy Brinsupri failed to meet its primary efficacy endpoint in a Phase 2 trial involving 150 patients with rare lung disease, triggering a sharp market reaction. The company announced the setback on Dec. 19, 2025, and its market...
A non‑profit, Fondazione Telethon, partnered with a U.S. charity to bring a lentiviral stem‑cell gene therapy for Wiskott‑Aldrich syndrome to market. The FDA approved the product, Waskyra etuvetidigene autotemcel, marking the first time a non‑profit acted as the regulatory applicant. The therapy...
Japan’s biotech industry is entering a growth phase as the government unveils a ¥200 billion fund and regulatory sandbox to speed drug development. Venture capital activity surged 45% year‑over‑year, fueling a wave of startups focused on gene therapy and rare‑disease platforms....
BioMarin Pharmaceutical announced a $4.8 billion acquisition of Amicus Therapeutics, a move designed to fuel a continuous stream of strategic deals. The transaction will bring two marketed orphan drugs—one for Fabry disease and another for Pompe disease—into BioMarin’s portfolio, together projected...
Cai has been appointed to replace Zhang as head of China Starch & Pharmaceutical Co. (CSPC), the country’s largest generic drug manufacturer. The transition was announced in December 2025 and is effective immediately. Cai brings a background in AI-driven drug...
The November 2025 Patent Highlights post serves as a gateway to Drug Hunter’s most‑read resources, including top‑10 lists of popular articles, reviews, and case studies from the year. It spotlights a detailed review of FcRn biology and the push toward oral...
The U.S. FDA has disclosed a draft overhaul that would tighten vaccine approval standards, requiring developers to submit expanded safety and efficacy data and potentially subject annual flu shots to large‑scale trials. Simultaneously, the CDC withdrew its universal hepatitis B vaccination...
Johnson & Johnson showcased a robust hematology pipeline at the ASH 2025 meeting, unveiling more than 60 new abstracts. The company highlighted real‑world evidence from thousands of patients, underscoring the efficacy of its CAR‑T, bispecific and gene‑editing therapies. Notably, the...
